Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.99 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.86 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.86 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.86 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.86 |
| ▸ | STK10 | O94804 | 1/20 | 0.86 |
| ▸ | ABL1 | P00519 | 1/20 | 0.86 |
| ▸ | INSR | P06213 | 1/20 | 0.86 |
| ▸ | RET | P07949 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.86 |
| ▸ | SRC | P12931 | 1/20 | 0.86 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.86 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.86 |
| ▸ | CDK2 | P24941 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL29356338 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL30680457 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL4097293 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL15408126 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL4926017 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL93590 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29866632 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL31732815 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL1374543 | 0.99 | ABCB11 (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL1651711 | 0.95 | EGFR (0.91) | EGFRERBB2ABCB11MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110318768-A1 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT | SYSMEX CORPORATION (JP) | 2011-12-29 | — | — | US | claimed |
| EP-3670539-A1 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | Daiichi Sankyo Europe GmbH (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3351558-A2 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | Daiichi Sankyo Europe GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| US-9988462-B2 | Material and methods for treating or preventing HER-3 associated diseases | DAIICHI SANKYO EUROPE GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-20180134805-A1 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | DAIICHI SANKYO EUROPE GMBH (DE) | 2018-05-17 | — | — | US | disclosed |
| US-9803025-B2 | Material and methods for treating or preventing HER-3 associated diseases | AMGEN, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9539257-B2 | Method of treating cancer | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-20160222126-A1 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | U3 PHARMA GMBH (DE) | 2016-08-04 | — | — | US | disclosed |
| US-20160096826-A1 | CO-CRYSTALS OF LAPATINIB MONOACID SALTS | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2016-04-07 | — | — | US | disclosed |
| US-20150231137-A1 | METHOD OF TREATING CANCER | SMITHKLINE BEECHAM (CORK) LIMITED | 2015-08-20 | — | — | US | disclosed |
| US-20110318768-A1 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT | SYSMEX CORPORATION (JP) | 2011-12-29 | — | — | US | disclosed |
| WO-2011060206-A2 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | U3 PHARMA GMBH (DE) | 2011-05-19 | — | — | WO | disclosed |
| US-20110053964-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | LEO OSPREY LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20080051422-A1 | 4-Aminoquinazoline derivatives and methods of use thereof | CONCERT PHARMACEUTICALS INC. (US) | 2008-02-28 | — | — | US | disclosed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-1294715-B1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-7157466-B2 | Quinazoline ditosylate salt compounds | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-01-02 | — | — | US | disclosed |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | NOVARTIS AG (CH) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | EGFR 1/4885ERBB2 3/4885ABCB11 3236/4885 |
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | ERBB4, ABL1, ERBB2 | EGFR 64/4885ERBB2 3/4885ABCB11 1630/4885 |
| US-20160096826-A1 | CO-CRYSTALS OF LAPATINIB MONOACID SALTS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ABCB11 384/4885 |
| US-20080051422-A1 | 4-Aminoquinazoline derivatives and methods of use thereof | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885ABCB11 232/4885 |
| US-20110053964-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885ABCB11 468/4885 |
| US-20150231137-A1 | METHOD OF TREATING CANCER | HLA-DRB1, HLA-B, TSG101 | EGFR 1129/4885ERBB2 1598/4885ABCB11 685/4885 |
| US-20030220354-A1 | Quinazoline ditosylate salt compounds | ERBB4, ABL1, ERBB2 | EGFR 64/4885ERBB2 3/4885ABCB11 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.